INDEPENDENT THINKING. TRACEABLE EVIDENCE.Research edition · 29 October 2026
Modern DosingTHE PRACTITIONER’S PERSPECTIVEA clearer view of
the peptide economy ↗
The research library / Safety
Safety / SOURCE-DATED ANALYSIS

Pancreatitis warnings without an incidence estimate

MHRA strengthened pancreatitis information for GLP-1 and dual GLP-1/GIP medicines, including rare necrotising and fatal cases.

What changed

MHRA strengthened pancreatitis information for GLP-1 and dual GLP-1/GIP medicines, including rare necrotising and fatal cases.

What the evidence does not settle

UK communication. Spontaneous reports are not population incidence estimates or proof of causation in each case.

Evidence record

Event date: 2026-01-29. Source review: inherited source synthesis; not re-audited in this expansion. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.

  1. Original source ↗

Revision history

29 October 2026: migrated from the research edition, retaining source links and evidence qualifications; not re-audited in the current expansion. Report a proposed correction through Contact us; do not include patient data.

THE MODERN DOSING WEEKLY

The peptide news
that changes your week.

Evidence-backed developments. The moves that matter. What each means for your practice or business—in one weekly email.